SAN DIEGO, July 15, 2014 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it was
granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor
Modulators," by the United States Patent and Trademark Office for
APD371, an agonist of the cannabinoid receptor 2 (CB2). Arena is
exploring several potential indications for APD371, including
chronic pain, and is currently conducting a Phase 1
single-ascending dose trial.
"Intellectual property protection is an important element of our
clinical-stage pipeline," said Jack Lief, Arena's President and
Chief Executive Officer. "This patent provides us further
confidence that APD371 can be exclusive to Arena until at least
2030."
Arena owns patents and pending patent applications covering
compositions of matter for APD371 and related compounds, as well as
methods of treatment utilizing APD371 and related compounds. Patent
applications for APD371 have been filed in 23 jurisdictions,
including the United States,
Europe, Japan and China. The jurisdictions where patent
applications have been filed are estimated to have accounted
for more than 95% of global pharmaceutical sales in
2011.
About Chronic Pain
In the US alone, an estimated 100 million adults are burdened
with chronic pain. Pain is the second leading cause of medically
related work absenteeism, with greater than 50 million workdays
lost each year. The annual US economic cost related to chronic pain
is estimated at $560-$635 billion.
The global pain management therapeutics market was estimated at
$29 billion in 2010.
About
APD371
APD371, an orally available agonist of the CB2 receptor, is an
internally discovered investigational drug candidate Arena is
exploring for several potential indications, including chronic
pain. This compound is designed to be highly selective to
provide pain relief without psychotropic effects and without the
potential for dependence or abuse. Preclinical efficacy with APD371
has been shown in animal models of pain.
About Arena Pharmaceuticals
Arena is embracing the challenge of improving health by seeking
to bring innovative medicines targeting G protein-coupled receptors
to patients. Arena's internally discovered drug, BELVIQ®
(lorcaserin HCl), is approved in the
United States, and Arena is focused on discovering,
developing and commercializing additional drugs to address unmet
medical needs. Arena's US operations are located in
San Diego, California, and its
operations outside of the United
States, including its commercial manufacturing facility, are
located in Zofingen, Switzerland.
For more information, visit Arena's website at
www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are registered service marks
of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of
Arena Pharmaceuticals GmbH.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about the
advancement, exploration, therapeutic indication, use, safety,
efficacy, selectivity, mechanism of action and potential of APD371;
patents, patent applications and patent protection for APD371,
including coverage, duration, the exclusivity provided by patents,
and the significance of the jurisdictions in which patent
applications have been filed; the importance of intellectual
property protection; the market for pain; embracing the challenge
of improving health; seeking to bring innovative medicines to
patients; and Arena's confidence, focus, plans, goals, strategy,
expectations, research and development programs, and ability to
discover and develop compounds and commercialize drugs. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include, but are not limited to, the following: Arena's
patent protection and ability to obtain and defend patents; risks
related to commercializing drugs, including regulatory,
manufacturing, supply and marketing issues and the availability and
use of BELVIQ; cash and revenues generated from BELVIQ, including
the impact of competition; Arena's revenues will be based in part
on estimates, judgment and accounting policies, and incorrect
estimates or disagreement regarding estimates or accounting
policies may result in changes to Arena's guidance or previously
reported results; the timing and outcome of regulatory review is
uncertain, and BELVIQ may not be approved for marketing when
expected or ever in combination with another drug, for another
indication or using a different formulation or in any other
territory for any indication; regulatory decisions in one territory
may impact other regulatory decisions and Arena's business
prospects; government and commercial reimbursement and pricing
decisions; risks related to relying on collaborative arrangements;
the timing and receipt of payments and fees, if any, from
collaborators; the entry into or modification or termination of
collaborative arrangements; unexpected or unfavorable new data;
nonclinical and clinical data is voluminous and detailed, and
regulatory agencies may interpret or weigh the importance of data
differently and reach different conclusions than Arena or others,
request additional information, have additional recommendations or
change their guidance or requirements before or after approval;
data and other information related to any of Arena's research and
development may not meet regulatory requirements or otherwise be
sufficient for (or Arena or a collaborator may not pursue) further
research and development, regulatory review or approval or
continued marketing; the timing, success and cost of Arena's
research and development; results of clinical trials and other
studies are subject to different interpretations and may not be
predictive of future results; clinical trials and other studies may
not proceed at the time or in the manner expected or at all; having
adequate funds; and satisfactory resolution of litigation or other
disagreements with others. Additional factors that could cause
actual results to differ materially from those stated or implied by
Arena's forward-looking statements are disclosed in Arena's filings
with the Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Contact: Arena Pharmaceuticals,
Inc.
|
Media Contact: Russo Partners
|
|
|
Craig M. Audet, Ph.D., Senior Vice
President,
Operations & Head
of Global Regulatory Affairs
caudet@arenapharm.com
858.453.7200, ext.
1612
|
David Schull, President
david.schull@russopartnersllc.com
858.717.2310
|
www.arenapharm.com
SOURCE Arena Pharmaceuticals, Inc.